Peptides having skin condition improving activity and uses thereof

Abstract

The present application relates to a peptide having skin condition-improving activity and its uses, and provides a peptide having the amino acid sequence of SEQ ID NO: 1, and a cosmetic composition for improving skin condition containing the peptide having the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

Description

Technical Field

[0001] The present invention relates to a peptide having skin condition improving activity and its use.

Background Art

[0002] Human skin is constantly undergoing changes, and the most typical ones are the decline in skin function due to aging and the decrease in visual beauty. Aging causes the formation of skin wrinkles, and typical factors for wrinkle formation include ultraviolet exposure and reduced biosynthesis of collagen. Skin aging can be broadly classified into endogenous aging due to genetic factors and exogenous aging due to external environmental factors such as sunlight. Among them, in the case of exogenous aging, it is known that aging can be prevented, treated, or delayed through, for example, active oxygen removal, fibroblast proliferation, and promotion of collagen biosynthesis.

[0003] Collagen, which is a major component of the extracellular matrix, is the main matrix protein produced by skin fibroblasts. Collagen forms most of the organic substances in the skin, tendon, bone, and teeth, and in particular, its content is high in bone and skin (dermis). Such collagen is reduced by aging and photoaging caused by ultraviolet irradiation, and it is known to be closely related to the formation of skin wrinkles. In addition, collagen plays an important role in wound healing, promoting the synthesis of collagen in damaged epithelium and allowing the wound to recover quickly without scarring. At the same time, it has been reported that if the biosynthesis of collagen is promoted and the density of the basal layer and the like becomes higher, the melanin pigment concentration per unit skin density will decrease, and the effect of brightening the skin tone can be expected.

[0004] Under such a technical background, extensive research has been conducted to improve skin conditions through mechanisms such as promoting collagen biosynthesis, proliferating and enhancing the activity of fibroblasts, etc. (Patent Document 1), but the actual situation is still imperfect.

Prior Art Documents

Patent Documents

[0005]

Patent Document 1

Summary of the Invention

Problems to be Solved by the Invention

[0006] One aspect provides a peptide consisting of the amino acid sequence of SEQ ID NO: 1.

[0007] Another aspect provides a cosmetic composition for improving skin condition containing, as an active ingredient, a peptide consisting of the amino acid sequence of SEQ ID NO: 1.

[0008] Other objects and advantages of the present application will become more apparent from the following detailed description together with the claims and the drawings. Contents not described in this specification can be sufficiently recognized and analogized by those skilled in the art within the technical field of the present application or similar technical fields, so the description thereof is omitted.

Means for Solving the Problems

[0009] Each description and embodiment disclosed in the present application can also be applied to each other description and embodiment. That is, all combinations of various elements disclosed in the present application belong to the scope of the present application. Also, it cannot be assumed that the scope of the present application is limited by the specific descriptions described below.

[0010] One aspect provides a peptide consisting of the amino acid sequence of SEQ ID NO: 1.

[0011] As used herein, the term "peptide" may mean a linear molecule formed by the binding of amino acid residues to each other by peptide bonds. The peptide can be produced by chemical synthesis methods known in the art, particularly solid-phase synthesis techniques or liquid-phase synthesis techniques (U.S. Patent No. 5,516,891). As a result of intensive efforts to develop a peptide having biologically effective activity, the present inventors have investigated a peptide consisting of the amino acid sequence of SEQ ID NO:1. Here, the biologically effective activity may exhibit any one or more selected from the following characteristics: (a) promotion of fibroblast or keratinocyte proliferation, (b) enhancement of the expression of type I collagen (Col1a1), fibronectin, or elastin, which are components of the extracellular matrix, (c) enhancement of the expression of skin barrier factors, such as sirtuin 1 (SIRT-1) or aquaporin 3 (AQP3), and (d) inhibition of fibroblast or keratinocyte death and reduction of the reactive oxygen species level. Therefore, the peptide can be utilized for improving skin conditions or for antioxidant uses.

[0012] The peptide may have a protecting group attached to the N-terminus or C-terminus of the peptide in order to acquire chemical stability, enhanced pharmacological properties (half-life, water absorbency, titer, efficacy, etc.), altered specificity (e.g., a broad spectrum of biological activities), and reduced antigenicity. In one specific example, the N-terminus of the peptide is bound to any one protecting group selected from the group consisting of an acetyl group, a fluoreonylmethoxycarbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group, a butoxycarbonyl group, an allyloxycarbonyl group, and polyethylene glycol (PEG: polyethylene glycol), and / or the C-terminus of the peptide may be bound to any one protecting group selected from the group consisting of an amino group (-NH2), a tertiary alkyl group, and an azide (-NHNH2). Further, the peptide may optionally further contain a targeting sequence, a tag, a labeled residue, an amino acid sequence produced for a specific purpose to increase the half-life or peptide stability.

[0013] As used herein, the term "stability" may mean not only in vivo stability that protects the peptide from the attack of proteolytic enzymes in vivo, but also storage stability (e.g., room temperature storage stability).

[0014] Another aspect provides a cosmetic composition for improving skin conditions, comprising, as an active ingredient, a peptide consisting of the amino acid sequence of SEQ ID NO: 1.

[0015] Among the terms or elements mentioned in the description regarding the peptide, those that are the same as those already mentioned are as described above.

[0016] As used herein, the term "improvement" may mean all acts related to the alleviation or treatment of a condition, for example, all acts that at least reduce a parameter related to the degree of a symptom.

[0017] As used herein, the term "skin condition improvement" comprehensively means the process of treating, reducing, or alleviating skin damage induced by intrinsic or extrinsic factors of the skin, or the effects thereof, etc., and can be interpreted, for example, as improvement of wrinkles, improvement of skin elasticity, wound healing, strengthening of the skin barrier, or suppression of skin aging, but is not limited thereto.

[0018] Here, "improvement of wrinkles", "improvement of skin elasticity", and "wound healing" may mean all actions that increase the total amount of extracellular matrix factors including promotion of collagen synthesis, etc. Also, "strengthening of the skin barrier" may mean strengthening the natural function of the skin to prevent external leakage of moisture and nutrients in the skin and prevent penetration of harmful substances such as bacteria and viruses into the skin. Also, "suppression of skin aging" may mean suppressing the decline in skin functions such as wrinkles, sagging of the skin, and reduction in elasticity. At this time, the skin aging is also photoaging, for example, skin aging caused by ultraviolet rays.

[0019] Conventional functional peptides, despite having effective biological activities, have shown disadvantages in that due to the size of the peptide itself, they cannot effectively penetrate into target tissues or target cells, or have a short half-life and disappear in the body in a short period of time. Incidentally, the cosmetic composition according to one embodiment is very excellent in terms of the skin penetration rate of the active ingredient, etc., and for example, when locally applied to the skin, it could effectively improve the skin condition.

[0020] According to one embodiment, it was possible to promote the proliferation of fibroblasts and keratinocytes and enhance the synthesis of components of the extracellular matrix and skin barrier factors. Also, the peptide was shown to be able to restore the inhibited activities of fibroblasts and keratinocytes and enhance their antioxidant efficacy. Therefore, the peptide can be utilized as an active ingredient of a cosmetic composition for improving skin conditions.

[0021] The cosmetic composition also includes, but is not limited to, a cosmetically effective amount of the peptide and / or a cosmetically acceptable carrier.

[0022] As used herein, the term "cosmetically effective amount" means an amount sufficient to achieve the skin-condition improving efficacy of the cosmetic composition.

[0023] The weight ratio of the peptide to the cosmetically acceptable carrier is, for example, also from 500:1 to 1:500, and by way of example, the weight ratio is from 450:1 to 1:450, from 400:1 to 1:400, from 350:1 to 1:350, from 300:1 to 1:300, from 250:1 to 1:250, from 200:1 to 1:200, from 150:1 to 1:150, from 100:1 to 1:100, from 80:1 to 1:80, from 60:1 to 1:60, from 40:1 to 1:40, from 20:1 to 1:20, from 10:1 to 1:10, from 8:1 to 1:8, from 6:1 to 1:6, from 4:1 to 1:4, or from 2:1 to 1:2, but is not limited thereto.

[0024] The cosmetic composition can be manufactured into any dosage form commonly manufactured in the art, for example, it can be formulated into solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansings, oils, powder foundations, emulsion foundations, wax foundations, and sprays, etc., but is not limited thereto. For example, it can be manufactured into the dosage forms of softening lotions, nourishing lotions, nourishing creams, massage creams, essences, eye creams, cleansing creams, cleansing foams, cleansing waters, packs, sprays or powders.

[0025] When the dosage form of the cosmetic composition is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicon, bentonite, silica, talc, zinc oxide, etc. can be used as the carrier component.

[0026] When the dosage form of the cosmetic composition is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder is used as the carrier component. For example, when it is a spray, a propellant such as chlorofluorohydrocarbon, propane / butane or dimethyl ether can also be included.

[0027] When the dosage form of the cosmetic composition is a solution or emulsion, a solvent, solubilizer or emulsifier is used as the carrier component. For example, it can also include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol fatty acid ester, polyethylene glycol or sorbitan fatty acid ester.

[0028] When the dosage form of the cosmetic composition is a suspension, a liquid diluent such as water, ethanol or propylene glycol; a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester; microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth, etc. can be used.

[0029] When the dosage form of the cosmetic composition is surfactant-containing cleansing, as the carrier component, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkyl amide betaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative or ethoxylated glycerol fatty acid ester, etc. can be used.

[0030] In order to further improve the skin penetration problem or stability problem, the peptide can be contained in nanosomes or nanoparticles. For example, the nanosomes can be manufactured by a microfluidizer using lecithin as a raw material and can be contained within the lecithin particles. As long as the manufacturing method of the nanosomes is known, any method can be used. It is desirable that the size of the nanosome particles is 30 to 200 nm. When the size of the nanosome particles is less than 30 nm, skin penetration proceeds very quickly and skin side effects occur. When it exceeds 200 nm, skin penetration is not easy and it may be difficult to obtain the effect of using the nanosome structure.

[0031] The components contained in the cosmetic composition, in addition to the peptide as the active ingredient and the carrier component, include components generally used in cosmetic compositions, and for example, can also include general auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances.

[0032] As the active ingredient contained in the cosmetic composition, the content of the peptide can be appropriately and non-restrictively selected according to the form of the product, the desired use, etc. For example, it can be added at 0.01 to 15% by weight of the total weight of the cosmetic composition. Also, for example, the cosmetic composition can contain the peptide at 1.0 to 3.0% by weight, preferably 2.0 to 3.0% by weight based on the total weight.

[0033] Still other aspects provide a method for improving skin condition, which includes applying a cosmetic composition containing a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to an individual's skin, and the use of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 for the manufacture of a composition for improving skin condition.

[0034] Among the terms or elements mentioned in the description related to the cosmetic composition, those that are the same as those already mentioned are as described above.

[0035] As used herein, the term "individual" means a subject in need of improving skin condition, and more specifically, means a human, or a mammal such as a non-human primate, mouse, dog, cat, horse, and cow.

[0036] As used herein, the terms "apply", "administer", and "coat" are used interchangeably and may mean bringing a composition according to an embodiment to at least partial localization to a desired site, or distributing a composition according to an embodiment into an individual by an administration route.

[0037] Still other aspects provide an antioxidant composition containing a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0038] Among the terms or elements mentioned in the description related to the peptide, those that are the same as those already mentioned are as described above.

[0039] The antioxidant composition may also be in the form of a pharmaceutical composition, a quasi-drug composition, or a cosmetic composition. As an example, the composition may be utilized in a cosmetic composition for improving skin condition, or a pharmaceutical composition for improving or treating a disease state related to skin damage.

[0040] According to one embodiment, it has been shown that the peptide can restore the inhibited activities of fibroblasts and keratinocytes and enhance their antioxidant efficacy. Therefore, the peptide can be utilized as an active ingredient of a composition for antioxidation.

[0041] As an example, the composition for antioxidation can be provided in the form of a pharmaceutical composition. The pharmaceutical composition includes, but is not limited to, a pharmaceutically effective amount of the peptide and / or a pharmaceutically acceptable carrier.

[0042] As used herein, the term "pharmaceutically effective amount" may mean an amount sufficient to achieve the prophylactic or therapeutic efficacy of a disease related to skin damage of the pharmaceutical composition.

[0043] The pharmaceutically acceptable carrier is commonly used in formulation and includes, but is not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, etc. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).

[0044] The weight ratio of the aforementioned peptide to the aforementioned pharmaceutically acceptable carrier is, for example, also 500:1 to 1:500. As an example, the weight ratio is 450:1 to 1:450, 400:1 to 1:400, 350:1 to 1:350, 300:1 to 1:300, 250:1 to 1:250, 200:1 to 1:200, 150:1 to 1:150, 100:1 to 1:100, 80:1 to 1:80, 60:1 to 1:60, 40:1 to 1:40, 20:1 to 1:20, 10:1 to 1:10, 8:1 to 1:8, 6:1 to 1:6, 4:1 to 1:4, or 2:1 to 1:2, but is not limited thereto.

[0045] In addition to the aforementioned components, the aforementioned pharmaceutical composition may also contain additives such as lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc., but is not limited thereto.

[0046] The aforementioned pharmaceutical composition is administered orally or parenterally, preferably parenterally. When administered parenterally, it can be administered by intramuscular injection, intravenous injection, subcutaneous injection, intraperitoneal injection, topical administration, transdermal administration, etc., but is not limited thereto.

[0047] The dosage of the aforementioned pharmaceutical composition is also 0.0001 to 1,000 μg, 0.001 to 1,000 μg, 0.01 to 1,000 μg, 0.1 to 1,000 μg, or 1.0 to 1,000 μg per day, but is not limited thereto. It can be formulated in various ways depending on factors such as the formulation method, administration method, patient's age, weight, sex, disease state, food, administration time, administration route, excretion rate, and reaction sensitivity.

[0048] The aforementioned pharmaceutical composition is manufactured in unit dosage form or can be manufactured by being contained in a multi-dose container by formulating it using a pharmaceutically acceptable carrier and / or excipient by a method that can be easily implemented by a person having ordinary knowledge in the technical field to which the invention belongs.

[0049] The dosage form is also in the form of a solution, suspension, or emulsion in an oily medium or an aqueous medium, and can also be in the form of an extract, powder, granule, tablet, or capsule, and can also contain a dispersant and / or a stabilizer added thereto.

[0050] Still another aspect provides a food composition for improving skin condition, which contains, as an active ingredient, a peptide consisting of the amino acid sequence of SEQ ID NO: 1.

[0051] Among the terms or elements mentioned in the description related to the peptide, those that are the same as those already mentioned are as described above.

[0052] The content of the peptide as an active ingredient contained in the food composition is appropriately and non - restrictively selected according to the form of the food, the desired use, etc. For example, it can be added at 0.01 to 15% by weight of the total food weight. Also, for example, a health beverage composition can be added at a ratio of 0.02 to 10 g, preferably 0.3 to 1 g, based on 100 ml.

Advantages of the Invention

[0053] According to the peptide according to one aspect, it can be applied to improving skin conditions including wrinkle improvement, skin elasticity improvement, wound healing, skin barrier strengthening, or skin aging suppression, etc., by promoting the proliferation of fibroblasts and keratinocytes and enhancing the synthesis of extracellular matrix components and skin barrier factors.

[0054] According to the peptide according to one aspect, it can contribute to recovering skin damage that may be caused by an external environment such as ultraviolet rays, by restoring the inhibited activities of fibroblasts and keratinocytes and enhancing their antioxidant efficacy.

[0055] Therefore, the peptide according to one aspect can be utilized as an active ingredient of a composition for improving skin conditions or a composition for antioxidation.

Brief Description of the Drawings

[0056]

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Mode for Carrying Out the Invention

[0057] Hereinafter, the present invention will be described in more detail through examples. However, these examples are for illustrative purposes of the present invention, and the scope of the present invention is not limited to these examples.

[0058] Example 1. Synthesis of Peptide Using an automatic peptide synthesizer (Milligen 9050 (Millipore, USA)), a peptide having the amino acid sequence of SEQ ID NO: 1 described in Table 1 below was synthesized, and C18 reverse-phase high-performance liquid chromatography (HPLC) (Waters Associates, USA) was used to purely separate the synthesized peptides. The column used was ACQUITY UPLC BEH300 C18 (2.1 mm X 100 mm, 1.7 μm (Waters Co., USA)).

[0059]

Table 1

[0060] Example 2. Confirmation of Growth-Promoting Effect on Skin Cells In this example, by evaluating the change in the survival rate of NIH3T3 cells, which are mouse fibroblasts, or HaCaT cells, which are human keratinocytes, the effect of the peptide according to one example on the growth of skin cells is confirmed.

[0061] Specifically, NIH3T3 cells or HaCaT cells were seeded in a 96-well plate at 5×10 3After seeding at the density of cells / well, it was cultured for 24 hours. Then, the cells were washed once with serum-free DMEM media, and the culture medium was replaced with the serum-free medium. Then, the peptide consisting of the amino acid sequence of SEQ ID NO: 1 was dispensed into the medium at 50 μM or 100 μM each, and it was cultured in a CO2 incubator at 37 °C for 72 hours. Then, the culture was washed twice with PBS, and then treated with a 4% paraformaldehyde (PFA) solution for 15 minutes to fix the cultured cells. Then, it was washed twice with distilled water, treated with an SRB solution for 1 hour for cell staining, washed with a 1% acetic acid solution, and then dried. Then, the dried culture was dissolved in 20 mM Tris buffer, and the absorbance at 560 nm was measured using a microplate reader (Molecular Devices, USA). In this example, the control group used the non-treated group, and as the positive control group, the group added with insulin-like growth factor (IGF) was used.

[0062] As a result, as shown in Fig. 1, it was confirmed that the peptide consisting of the amino acid sequence of SEQ ID NO: 1 promoted the proliferation of fibroblasts and keratinocytes.

[0063] Example 3. Confirmation of wrinkle improvement and elasticity enhancement effects In this example, by evaluating the expression levels of type I collagen (Col1a1), fibronectin or elastin, which are known as components of the dermis, the effect of the peptide according to one example on improving endogenous skin aging including wrinkle improvement and elasticity enhancement is confirmed.

[0064] Specifically, NIH3T3 cells were seeded in a 6-well plate at 3×10 5After seeding at a cell / well density, it was cultured for 24 hours. Then, the cells were washed once with serum-free DMEM media, and the culture medium was replaced with the serum-free medium. Then, the peptide consisting of the amino acid sequence of SEQ ID NO: 1 was dispensed into the medium at 50 μM or 100 μM each, and it was cultured in a CO2 incubator at 37 °C for 24 hours. Then, the culture was washed twice with PBS, and RNA was separated from the culture using easy BLUE (iNtRON, Korea). Using an RT Kit (Enzynomics, Korea), 1 μg of the previously separated RNA was reverse-transcribed to synthesize respective cDNAs. Then, polymerase chain reaction (PCR) was performed using the cDNA and primers for Col1a1, fibronectin, and elastin. Note that as the control group, an untreated group was used, and as the positive control group, a group to which TGF-β1 was added (TGF-β1) was used, and the nucleotide sequences of the primers used in this example are as shown in Table 2 below.

[0065]

Table 2

[0066] As a result, as shown in FIGS. 2 and 3, it was confirmed that the expression of Col1a1, fibronectin, and elastin, which are components of the extracellular matrix, was increased by the peptide consisting of the amino acid sequence of SEQ ID NO: 1. Through the above results, it was found that the peptide according to an embodiment contributes to the improvement of intrinsic skin aging including wrinkle improvement and elasticity enhancement by increasing the components of the extracellular matrix.

[0067] Example 4. Confirmation of Skin Barrier Strengthening Effect In this example, by evaluating the expression levels of sirtuin 1 (SIRT-1) or aquaporin 3 (AQP3), the effect of the peptide according to an embodiment on skin barrier strengthening is confirmed.

[0068] Specifically, HaCaT cells were seeded in a 6-well plate at a density of 3×10 5 cells / well and then cultured for 24 hours. Thereafter, the cells were washed once with serum-free DMEM media, and the culture medium was replaced with the serum-free medium. Then, the peptide consisting of the amino acid sequence of SEQ ID NO: 1 was dispensed into the medium at 50 μM or 100 μM each, and it was cultured in a CO2 incubator at 37 °C for 24 hours. Then, the culture was washed twice with PBS, and RNA was separated from the culture using easy BLUE (iNtRON, Korea). Using an RT Kit (Enzynomics, Korea), 1 μg of the separated RNA was reverse-transcribed to synthesize respective cDNAs. Then, polymerase chain reaction was performed using the cDNA and primers for sirtuin 1 and aquaporin 3. Note that as the control group, an untreated group was used, and as the positive control group, a group to which EGF was added (EGF) was used. The nucleotide sequences of the primers used in this example are as shown in Table 3 below.

[0069]

Table 3

[0070] As a result, as shown in FIGS. 4 and 5, it was confirmed that the expression of SIRT-1 and AQP3, which are skin barrier factors, was increased by the peptide consisting of the amino acid sequence of SEQ ID NO: 1. Through the above results, it was found that the peptide according to one example contributes to skin barrier strengthening and skin anti-aging by increasing skin barrier factors.

[0071] Example 5. Confirmation of inhibitory effect on death of skin cells induced by ultraviolet rays In this example, by evaluating the change in survival rate of skin cells whose death was induced by ultraviolet irradiation, the effect of the peptide according to one example on suppression of death or cell recovery of skin cells induced by ultraviolet rays was confirmed.

[0072] Specifically, after seeding NIH3T3 cells or HaCaT cells in a 96-well plate at a density of 1×10 4 cells / well, they were cultured for 24 hours. Then, the cells were washed once with serum-free DMEM media, the culture medium was replaced with the serum-free medium, and then a peptide consisting of the amino acid sequence of SEQ ID NO: 1 was dispensed at 50 μM or 100 μM each. The culture medium with the dispensed peptide was cultured in a CO2 incubator at 37°C for 1 hour, transferred to an E-TUBE, mixed with 100 μl of PBS, and dispensed into the well plate. Then, using an ultraviolet irradiation machine (Vilber Lourmat, France), NIH3T3 cells were irradiated with ultraviolet light at 6 J / cm 2 and HaCaT cells were irradiated with ultraviolet light at 15 mJ / cm 2 . Then, the PBS in the well plate was removed, 900 μL of the culture medium with the dispensed peptide was added, and cultured in a CO2 incubator at 37°C for 72 hours. Then, the culture was washed twice with PBS, and then treated with a 4% paraformaldehyde (PFA) solution for 15 minutes to fix the cultured cells. Then, it was washed twice with distilled water, treated with an SRB solution for 1 hour for cell staining, washed with a 1% acetic acid solution, and then dried. Then, the dried culture was dissolved in 20 mM Tris buffer, and the absorbance at 560 nm was measured using a microplate reader (Molecular Devices, USA). In this example, the control group used the non-treated group, and as the positive control group, the group with Trolox added (Trolox) was used.

[0073] As a result, as shown in FIG. 6, it was confirmed that the cell viability of fibroblasts and keratinocytes reduced by ultraviolet irradiation was restored by the peptide consisting of the amino acid sequence of SEQ ID NO: 1. Through the above results, it was found that the peptide according to one example contributes to the suppression of ultraviolet-induced skin cell death.

[0074] Example 6. Confirmation of antioxidant effect on skin cells induced by ultraviolet rays In this example, by evaluating the level of intracellular reactive oxygen species increased by ultraviolet irradiation, the effect of the peptide according to one example on the antioxidant effect in skin cells induced by ultraviolet rays is confirmed.

[0075] Specifically, NIH3T3 cells or HaCaT cells were seeded in a 6-well plate at a density of 5×10 5 cells / well, and then cultured for 24 hours. After that, the cells were washed once with serum-free DMEM media, the culture medium was replaced with the serum-free medium, and then the peptide consisting of the amino acid sequence of SEQ ID NO: 1 was dispensed at 50 μM or 100 μM each. The culture medium containing the dispensed peptide was cultured in a CO2 incubator at 37 °C for 1 hour, transferred to an E-TUBE, mixed with 100 μl of PBS, and dispensed into the well plate. Then, using an ultraviolet irradiation machine (Vilber Lourmat, France), NIH3T3 cells were irradiated with ultraviolet rays of 6 J / cm 2 and HaCaT cells were irradiated with ultraviolet rays of 15 mJ / cm 2 . After that, the PBS in the well plate was removed, 900 μL of the culture medium containing the dispensed peptide was added, and then cultured in a CO2 incubator at 37 °C for 24 hours. Then, 2’,7’-dichlorofluorescein diacetate (DCFG-DA) was added to the culture, wrapped with foil, and then cultured in a CO2 incubator at 37 °C for 30 minutes. Then, it was washed twice with PBS, and after treating with 500 μL of 1× trypsin / EDTA to obtain cells, centrifugation was performed. After washing the centrifuged cells with PBS, the FL1 fluorescence value was measured via flow cytometry (FACS (BD Biosciences, USA)). In this example, as the control group, the non-treated group was used, and as the positive control group, the group added with Trolox (Trolox) was used.

[0076] As a result, as shown in Fig. 7, it was confirmed that the level of reactive oxygen species in fibroblasts and keratinocytes increased by ultraviolet irradiation was reduced by the peptide consisting of the amino acid sequence of SEQ ID NO: 1. Through the above results, it was found that the peptide according to one embodiment contributes to the antioxidant effect on skin cells induced by ultraviolet rays.

[0077] Formulation Example 1. Softening Lotion A softening lotion containing the peptide according to one embodiment and having the following composition was produced by adopting a method known in the art.

[0078] [Table 4]

[0079] Formulation Example 2. Nutritional Cream A nutritional cream containing the peptide according to one embodiment and having the following composition was produced by adopting a method known in the art.

[0080] [Table 5]

[0081] Formulation Example 3. Nutritional Lotion A nutritional lotion containing the peptide according to one embodiment and having the following composition was produced by adopting a method known in the art.

[0082] [Table 6]

[0083] Formulation Example 4. Essence An essence containing the peptide according to one embodiment and having the following composition was produced by adopting a method known in the art.

[0084] [Table 7]

[0085] The foregoing description of the present invention is for illustrative purposes, and those having ordinary knowledge in the technical field to which the present invention pertains will be able to understand that the present invention can be easily deformed into other specific forms without changing the technical idea and essential features of the present invention. Therefore, the embodiments described above are to be understood as illustrative in all respects and not restrictive.

Claims

1. A peptide consisting of the amino acid sequence of SEQ ID NO:

1.

2. The peptide according to Claim 1, wherein the N-terminus of the peptide is bound to any one of the protecting groups selected from the group consisting of an acetyl group, a fluoreonylmethoxycarbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group, a butoxycarbonyl group, an allyloxycarbonyl group, and polyethylene glycol (PEG).

3. The C-terminus of the peptide is bonded to any one protecting group selected from the group consisting of an amino group (-NH ２ ), a tertiary alkyl group, and an azide (-NHNH ２ ). The peptide according to claim 1.

4. The peptide according to Claim 1, wherein the peptide exhibits any one or more selected from the following characteristics: (a) Promotion of the proliferation of fibroblasts or keratinocytes; (b) Enhancement of the expression of type I collagen (Col1a1), fibronectin, or elastin, which are components of the extracellular matrix; (c) Enhancement of the expression of sirtuin 1 (SIRT-1) or aquaporin 3 (AQP3), which are skin barrier factors; and (d) Inhibitor of the death of fibroblasts or keratinocytes, and reduction of the reactive oxygen species level.

5. A cosmetic composition for improving skin condition, comprising the peptide according to any one of Claims 1 to 4 as an active ingredient.

6. The cosmetic composition according to Claim 5, wherein the improvement of the skin condition is improvement of wrinkles, improvement of skin elasticity, wound healing, strengthening of the skin barrier, or suppression of skin aging.

7. The cosmetic composition according to Claim 6, wherein the skin aging is skin aging caused by ultraviolet rays.

Images